Business Wire

Octant Launches Polypharmacology Drug Discovery Engine for Complex Diseases with $30 Million Series A Financing Led by Andreessen Horowitz

EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc., a synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases announced that it has raised ...
MedCity News

BMS joins Octant’s $80M financing and signs on as a drug discovery partner

Octant Bio set out on a journey to show that the convergence of synthetic biology, chemistry, and computational techniques could lead to new drugs for patients. That destination is still distant, but ...
FierceBiotech

Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnership

Data-driven therapeutics company Octant Bio is exploring new frontiers of drug development with $80 million in-pocket and a freshly signed Big Pharma partnership. Octant—a historical instrument used ...
Business Wire

Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments

EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc. (“Octant” or the “Company”), a next-generation, data-driven therapeutics company developing programmable biology and chemistry to build precision ...
TechCrunch

Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery

Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the ...
Nasdaq

Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

“We have been working with Mark for over a year as a Board Member and are thrilled to share that he’s now working with us day-to-day,” said Sri Kosuri, CEO of Octant. “Mark’s unique experience and ...